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Abstract 
Background: During the COVID-19 lockdown period in the United Kingdom that began on March 23, 2020, more than a 
quarter of a million people with cancer reported worsening mental health. Help to Overcome Problems Effectively (Hope) is a 
self-management program for people with cancer, designed to provide support for distress, unmet needs, and poor psychological 
health. In light of social distancing during the COVID-19 pandemic, digital delivery of the Hope Programme has become ever 
more vital for people with cancer. Previous pre-post studies of the digital Hope Programme have found reduced anxiety and 
depression and improved well-being for people with cancer. However, evaluation of this evidence has been limited by the lack 
of a control group in these previous studies. 
Objective: We now present a protocol for a feasibility randomized controlled trial of the digital Hope Programme for people 
with cancer during the COVID-19 pandemic. Primary outcomes will be recruitment, dropout, and adherence rates, and estimations 
of sample and effect size. To detect signals of efficacy, secondary outcomes will be participant mental health and well-being. 
Methods: Participants will be recruited by Macmillan Cancer Support (MCS) through their social media networks. The study 
will employ a feasibility wait-list randomized controlled trial (RCT) design, with people with cancer being randomized to join 
the digital Hope Programme immediately (intervention group [IG]) or join a 6-week waiting list (wait-list control group [WLCG]) 
with a 1:1 allocation ratio. Participants will complete digital measures of depression, anxiety, mental well-being, and confidence 
in managing their own health. Online questionnaires will be administered preprogram and 6 weeks postprogram. 
Results: All people who had requested access to the Hope Programme from MCS (N=61) will be invited to participate in the 
trial. Baseline data collection commenced in April 2020, and the Hope Programme began for the IG in May 2020 and for the 
WLCG in June 2020. Postprogram data collection was completed by the end of August 2020. 
Conclusions: This feasibility study will provide data to inform the design of a future definitive trial. Wider-scale provision of 
the digital Hope Programme has potential to improve the lives of thousands of people with cancer and reduce the burden on health 
care providers during these unprecedented times. 
Trial Registration: ISRCTN Registry ISRCTN79623250; http://www.isrctn.com/ISRCTN79623250 
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Introduction 
Background and Rationale 
The COVID-19 pandemic has created additional challenges for 
people with cancer, both in terms of physical and mental health. 
Many people with cancer are considered at increased risk of 
serious complications if they were to contract the COVID-19 
virus [1]. People with cancer have reported concerns about the 
further risks to their health from COVID-19, increased anxiety 
relating to potential cancellation or reduction in treatments and 
advice from oncology and other medical teams, and significant 
anxiety and fears of contracting COVID-19 as restrictions in 
lockdown arrangements are eased [2]. The pandemic has 
negatively impacted both the cancer health systems and the 
people using them. Overall, 1 in 5 (20%) people with cancer in 
the United Kingdom report that they will not feel safe enough 
to leave their home until an effective treatment or vaccine for 
COVID-19 becomes widely available [3]. 
People with cancer are already known to face challenges 
following primary treatment, including fatigue, pain, sexual 
problems, issues with cognitive functioning, depression, anxiety, 
social isolation, and financial issues [4-8]. A significant number 
of patients with cancer experience long-term negative impacts 
on their psychological well-being and mental health, including 
hypervigilance, anxiety, posttraumatic stress, and depression 
[9-14]; indeed, 2 years postdiagnosis, up to 20% met criteria 
for major depression and up to 40% met criteria for an anxiety 
disorder [13,14]. Many of these difficulties are experienced 
long-term, after regular contact with health care professionals 
has ceased, which leads to many patients feeling vulnerable and 
unsupported [5,7,8]. A recent review published before the 
COVID-19 pandemic came to light highlights the need for 
urgent research into the longer-term effects of cancer treatment 
on mental health, as increasing numbers of people live with and 
beyond cancer [15]. During lockdown, one in four (28%) people 
with cancer have experienced depression, anxiety, and stress, 
and one in seven (14%) people with cancer experienced further 
decline in their physical health (eg, sleep problems, extreme 
tiredness, and pain) [3]. Macmillan Cancer Support (MCS) have 
called for the UK government to ensure that holistic physical 
and mental health support for people with cancer is not forgotten 
as a result of the COVID-19 pandemic [3]. 
In the United Kingdom, the National Health Service (NHS) 
“Long Term Plan” of 2019 [16] places great emphasis on the 
need for holistic, person-centered care, with greater digital 
delivery for both NHS services overall and specifically those 
relating to living well with and beyond cancer. A holistic 
approach is timely, as recent research shows complex 
interrelationships between fatigue, fear of cancer recurrence, 
anxiety, and depression in people with cancer [17,18]. In 
response to the COVID-19 pandemic, there has also been a 
rapid and essential growth in the provision of health care 
digitally, to allow remote care [19,20]. A recent review and 
meta-analysis showed that digital psychoeducational 
interventions are effective in significantly reducing depression 
and fatigue in people with cancer [21]. Many people, including 
older adults, have become more motivated to use, accepting of, 
and familiar with digital technologies for health care and social 
connection [22]. This is essential to meet the needs of people 
with cancer, as traditional face-to-face support is cancelled and 
social isolation increases, particularly as in the United Kingdom 
and many other countries, people with cancer are being advised 
by the government to isolate or “shield” from others for 
prolonged periods [23,24]. 
Around 10 years ago, in response to the shortage of available, 
tailored self-management support for people with cancer, we 
codesigned a program together with people with cancer, 
clinicians, and other experts. The result was a group-based 
self-management program called the Help to Overcome 
Problems Effectively Program, known as the “Hope 
Programme,” for survivors of all types of cancer [25,26], which 
was originally delivered in-person. The Hope Programme 
recognizes the common challenges and unmet needs across all 
types of cancer including fatigue and psychological distress 
[4-14]. The Hope Programme differs from many other cancer 
self-management programs due to its roots in positive 
psychology [27-29] and its focus on hope and gratitude [30] to 
improve well-being and coping. It has been delivered in person 
to groups of survivors of all cancers and specifically for 
survivors of breast cancer, and participants have reported feeling 
more confident and hopeful and less alone [25,26]. The 
face-to-face version has been adapted for digital delivery, and 
initial pretest-posttest evaluation suggested potential effects on 
anxiety, depression, and positive well-being, with positive user 
evaluations [31]. A feasibility randomized controlled trial (RCT) 
study is the next step in the testing of this digital intervention 
and is required to assess whether participants consent to being 
randomized, and to test the feasibility of operating a wait-list 
control group. Owing to COVID-19, in-person service provision 
has largely been cancelled and this presents the opportunity to 
conduct the feasibility RCT of the digital intervention. This 
protocol has been prepared in accordance with SPIRIT (Standard 
Protocol Items: Recommendations for Interventional Trials) 
guidelines for clinical trials [32]. 
Objectives 
The aim of this study is to test the feasibility of a digitally 
delivered self-management program for people with cancer. 
This will inform the design of a definitive RCT. Additionally, 
preliminary assessment of the impact of the Hope Programme, 
via secondary outcomes, will be used to assess signals of 
efficacy in a trial context. 
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The planned primary outcomes (trail feasibility objectives) of 
the study are to investigate the following: 
• Recruitment rates for participation and for randomization 
• Retention and follow-up rates as the participants move 
through the trial 
• Adherence rates to study procedures, intervention 
attendance, and engagement 
• Sample size and effect size estimation for a definitive trial 
• Progression criteria for a definitive trial 
The secondary outcomes are the following: 
• Measures of depression, anxiety, confidence to self-manage 
cancer (patient activation), and mental well-being, as 
indicated by scores on validated measures 
Trial Design 
This study will employ a feasibility, randomized wait-list control 
group design, to explore the feasibility of a trial of the digital 
Hope Programme for people with cancer. The intervention is a 
6-week digital self-management program. Quantitative 
monitoring of participant progress through the online program 
will be undertaken. Participants will be asked to complete 
standardized measures of depression, anxiety, mental well-being, 
and confidence in managing their cancer. 
Methods 
Study Settings 
This is a digital study and the recruitment, intervention, and 
data collection will be carried out entirely online. Participants 
are referred by MCS. 
Eligibility Criteria 
Inclusion criteria for the feasibility RCT are the following: 
• Diagnosis of any type of cancer, at any stage 
• Adult (≥18 years) 
• Located in the United Kingdom 
• Access to the internet and a device that will allow them to 
engage with the intervention 
• Fluent in English to be able to engage with all the material 
in the intervention 
• Not recruited via the NHS 
Intervention 
The Hope Programme will be delivered by Hope for the 
Community (H4C) Community Interest Company, which is a 
research social enterprise spinout company from Coventry 
University [33]. Full details of the digital Hope Programme 
content are described in Multimedia Appendix 1. All Hope 
Programme modules have the same structure and format, 
consisting of quizzes, videos, educational content, activities 
with homework suggestions, and a module review page. The 
digital Hope Programme is adapted from the in-person Hope 
Programme, which was developed in conjunction with cancer 
survivors and MCS staff. The Hope Programme content 
comprises text, images, downloadable documents, and links to 
external websites. The content delivered is configured into 
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that can be used by participants to learn and consolidate the 
program content. The Hope Programme uses forums and 
messaging facilities that act as a conduit for communication 
between participants and facilitators. The Hope Programme is 
asynchronous, and content is released at set times over the 6 
weeks. The Hope Programme is moderated by trained peer 
facilitators. 
Primary Outcome Measures (Trial Feasibility 
Objectives) 
Recruitment Rates 
Recruitment rates for participation and randomization will be 
collected through Qualtrics. All eligible participants identified 
by MCS will be sent a link to the Qualtrics study survey, so we 
will calculate recruitment rates from those providing consent 
and/or completing baseline questionnaires. 
Retention and Follow-up Rates 
Follow-up will be online. Participants who become lost to 
follow-up will be identified through Qualtrics as those not 
completing postprogram questionnaires. It is possible that these 
participants may still complete some or all of the Hope 
Programme, and so participant retention can be identified 
separately through engagement with the Hope platform (see 
below). Participants who explicitly request to be withdrawn 
from the study will be categorized accordingly, but we will not 
contact participants to obtain reasons for not completing 
questionnaires. 
Adherence Rates 
The Hope platform collects user engagement data such as login 
frequency and duration, which assists the moderators with 
participant engagement and experience. Participants also have 
the option of receiving system-generated automatic nudge 
reminders sent to their email address. We will analyze this user 
engagement data to generate usage patterns and provide an 
overview of session attendance and participant engagement. 
Sample Size and Effect Size Estimation 
To inform sample size estimation for a future definitive trial, 
we will calculate the standard deviations of the continuous 
secondary outcomes pertaining to depression, anxiety, mental 
well-being, and participant confidence in managing their cancer. 
To estimate potential effect sizes for a primary outcome in a 
future definitive trial (namely, change in scores on key 
secondary outcome measures from preprogram to postprogram), 
we will calculate the difference between the mean difference 
preprogram and postprogram for the intervention and control 
groups and divide by the pooled standard deviation at baseline 
[34]. 
Progression Criteria 
We will collate the data from all participants in this feasibility 
RCT to inform progression to a definitive trial, based on the 
following criteria: 
• Recruitment rate >70% of eligible participants consented 
• Questionnaire completion rate >70% of participants 
completing T1 questionnaires 
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• Program completion rate >50% of participants attending 
all 6 Hope Programme sessions 
Secondary Outcome Measures 
We will administer a sociodemographic and health questionnaire 
at baseline only, requesting the following personal information 
from participants: gender, age, ethnicity, marital status, highest 
level of education, employment and occupation, and some 
details about their cancer diagnosis and any other medical 
conditions. 
Participants will complete a set of validated questionnaires 
preprogram and postprogram, to give an indication of changes 
in depression, anxiety, mental well-being, and confidence to 
self-manage their cancer across the intervention and control 
groups. These questionnaires are detailed below. 
The Patient Health Questionnaire (PHQ-9) [35] is a 9-item 
measure that assesses the frequency of depression symptoms 
(eg, “over the past two weeks, how often have you been bothered 
by any of the following problems … i) little interest or pleasure 
in doing things; ii) feeling down, depressed or hopeless; iii) 
poor appetite or overeating”). Responses to each of the 9 items 
range from 0 to 3 (0=not at all, 1=several days, 2=more than 
half the days, 3=nearly every day), leading to a summed score 
between 0-27, with higher scores indicating greater severity of 
depression. Scores of ≥10 are presumed to be above the clinical 
range, and so scores of ≥10 are classed as “cases” of depression. 
Recovery rates are calculated as those patients who score ≥10 
(cases) prior to treatment and <10 posttreatment. 
The Generalized Anxiety Disorder scale (GAD-7) [36] is a 
7-item scale measuring symptoms of generalized anxiety 
disorder (eg, “Over the past two weeks, how often have you 
been bothered by the following problems … i) feeling nervous, 
anxious or on edge; ii) trouble relaxing; iii) becoming easily 
annoyed or irritable”). Responses to all 7 items range from 0 to 
3 (0=not at all, 1=several days, 2=more than half the days, 
3=nearly every day), providing a total score of 0-21, with higher 
scores indicating greater anxiety. Scores of ≥8 are classed as 
“cases” of generalized anxiety disorder. Recovery rates are 
calculated as those patients who score ≥8 (cases) prior to 
treatment and <8 posttreatment. 
The Warwick Edinburgh Mental Wellbeing Scale (WEMWBS) 
[37] is a scale of 14 positively worded feelings and thoughts, 
used to assess mental well-being within the adult population. 
The scale includes measures of positive affect, satisfying 
interpersonal relationships, and positive functioning (eg, “Below 
are some statements about feelings and thoughts. Please tick 
the box that best describes your experience of each over the last 
two weeks … i) I’ve been feeling optimistic about the future; 
ii) I’ve been thinking clearly; iii) I’ve been feeling loved”). 
Participants rate each of the 14 items on a scale of 1 to 5 
(1=none of the time, 2=rarely, 3=some of the time, 4=often, 
5=all of the time), providing a total positive mental well-being 
score ranging from 14-70, with higher scores representing 
greater positive mental well-being. A change of ≥3 is seen as a 
clinically “meaningful” change [38]. 
The Patient Activation Measure (PAM) [39] is a validated, 




findings from a large number of studies. It helps to measure the 
spectrum of knowledge, skills, and confidence in patients and 
captures the extent to which people feel engaged and confident 
in taking care of their condition. 
Individuals are asked to complete a short survey and based on 
their responses, they receive a PAM score (0-100). The resulting 
score places the individual at one of four levels of activation, 
each of which reveals insight into a range of health-related 
characteristics, including behaviors and outcomes. The 4 levels 
of activation are the following: 
Level 1: Individuals tend to be passive and feel overwhelmed 
by managing their own health. They may not understand their 
role in the care process. 
Level 2: Individuals may lack the knowledge and confidence 
to manage their health. 
Level 3: Individuals appear to be taking action but may still 
lack the confidence and skill to support their behaviors. 
Level 4: Individuals have adopted many of the behaviors needed 
to support their health but may not be able to maintain them in 
the face of life stressors. 
Participant Timeline 
Participants referred by MCS will be sent an email from H4C, 
with brief information about the Hope Programme and the 
feasibility study. The email will contain a link to a Qualtrics 
survey that contains digital versions of (1) the participant 
information sheet (PIS), (2) the consent form, and (3) study 
questionnaires. The PIS and consent form are included in 
Multimedia Appendix 2. Participants are explicitly informed 
that they will be randomly assigned to one of two Hope 
Programmes, starting either in May or in June. Informed consent 
will be obtained online in accordance with relevant UK 
legislation (ie, Data Protection Act 2018). The PIS and consent 
form must be read and agreed to (eg, by checking relevant 
boxes) before the participant can proceed to the study 
questionnaires. 
After providing informed consent to take part in the study, all 
participants will be guided through the process of completing 
the baseline questionnaires (Time 0; hereafter, T0). Upon 
completion of T0 questionnaires, participants will be randomized 
via the Qualtrics randomization function, to either attend the 
Hope Programme starting in May 2020 (intervention group 
[IG]) or in June 2020 (wait-list control group [WLCG]). 
Participants are notified which group they have been randomized 
to at the end of the survey. There will be approximately 30 
participants in each group. The IG will then be sent an email 
link that provides access to the Hope Programme. Those 
randomized to the WLCG will be informed that they will receive 
an email link shortly before the start of the Hope Programme 
in June (ie, approximately 6 weeks later). After 6 weeks (T1), 
all participants will be emailed a link to the Qualtrics survey 
containing the secondary outcome questionnaires, and IG 
participants will also receive a participant debrief at T1. The 
debrief contains information reminding the participant why the 
study is being conducted and what will happen to the results, 
thanking them for their time, and includes sources of additional 
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support if they experienced any distress through completing the all digital study documents presented to participants at each 
questionnaires, such as their own general practitioner or the time point (T0, T1, T2). All information and questionnaires at 
Samaritans. The WLCG also receive the survey link via email T0, T1, and T2 will be delivered via the Qualtrics survey 
again, with secondary outcome measures and debrief, after they platform. The Hope Programme will be delivered via the H4C 
have received the intervention (T2). Table 1 provides a list of platform. 
Table 1. Information and questionnaires presented to IG and WLCG participants at each time point (T0, T1, and T2), across the duration of the study.a 
Study documents T0 T1 T2 
IG and WLCG IG WLCG WLCG 
Participant information sheet ✓ 
Informed consent ✓ 
Sociodemographic and health questionnaire ✓ 
Warwick Edinburgh Mental Wellbeing Scale ✓ ✓ ✓ ✓ 
Patient Health Questionnaire ✓ ✓ ✓ ✓ 
Generalized Anxiety Disorder scale ✓ ✓ ✓ ✓ 
Patient Activation Measure ✓ ✓ ✓ ✓ 
Poststudy debrief information ✓ ✓ 
aT0 refers to the beginning of the study; T1 is 6 weeks later, after the intervention group (IG) has completed the Hope Programme; T2 is an additional 
6 weeks later, after the wait-list control group (WLCG) has completed the Hope Programme. 
Sample Size 
Participants for this feasibility RCT were drawn from an 
opportunity sample, referred by MCS, of people with cancer 
who had expressed an interest in joining the Hope Programme 
(N=61). As a feasibility study, it was not necessary to conduct 
sample size calculations to power the study [40]. An arbitrary 
sample size of n=40 was deemed appropriate for this feasibility 
study, informed by similar studies in this area [41]. 
Recruitment 
We contacted all 61 people with cancer from an opportunity 
sample of people who expressed interest in attending the 
in-person MCS Hope Programme and invited them to participate 
in a trial of the digital program. MCS originally recruited these 
participants through their social media networks (eg, Macmillan 
Facebook page and website) and Macmillan Information 
Centres. Given the urgent need to provide immediate support 
during the COVID-19 crisis, we did not want to delay the study 
by seeking National Health Service (NHS) ethics approval to 
recruit NHS patients. Instead, with University ethics approval 
in place, we only recruited participants who were recruited via 
non-NHS sources such as the MCS website and their social 
media networks. Participant recruitment flow is depicted in 
Figure 1. 
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Figure 1. Flow diagram showing participants' route through the study. 
Assignment of Intervention 
Allocation Sequence Generation 
The participants will be randomly assigned to the IG or WLCG 
using a 1:1 allocation ratio. Randomization and the allocation 
sequence will be generated automatically on completion of the 
online consent form and baseline questionnaires, using the 
randomization function in Qualtrics Survey Software (Qualtrics). 
The research team will be unable to influence any aspect of the 
randomization procedure. 
Allocation Concealment Mechanism 
Participants were informed upon completion of the T0 
questionnaires, via a notification in Qualtrics, whether they had 
been randomized to the IG (in this case, starting in May 2020), 
or the WLCG (in this case, starting in June 2020). The research 
team remained unaware of participant allocation until group 
contact lists were created at the next data collection point (ie, 
T1). 
Blinding 
It will not be possible to “blind” participants to allocation. 
Analysis of outcome measures will be conducted blind to 
participant allocation where possible (eg, IG and WLCG data 
will be arbitrarily renamed “Group A” and “Group B” for the 




Data Collection, Management, and Analysis 
Data Collection Methods 
All data will be collected via online questionnaires administered 
through Qualtrics. The validated questionnaires (PHQ-9, 
GAD-7, WEMWBS, and PAM) have been described in the 
section on Objectives above. Participants will be entered into 
a prize draw to win a £50 Amazon voucher as an incentive to 
complete all study questionnaires. 
Data Management 
Each participant in this study will have a unique identifier (ID) 
generated by Qualtrics at enrollment, and this will be used to 
link participants’ survey data together at the end of the trial. 
The user engagement and analytics data collected by the Hope 
platform will be linked to the survey data by the unique ID. The 
linked survey and analytics data will be prepared initially in 
Microsoft Excel (Microsoft Corp) format, and will then be 
exported to IBM SPSS Statistics 26 (Version 26; IBM Corp), 
cleaned, and checked for missing values (all data will remain 
within the shared, password-protected project folder). Once the 
research team agree that all required data is present and 
complete, all survey data will be permanently deleted from 
Qualtrics. The complete anonymized research data files will be 
stored on the research team’s shared, password-protected project 
folder located on the university server. To comply with UK 
regulations (ie, General Data Protection Regulation and the 
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Data Protection Act 2018), the research data will be retained 
for 3 years after the study has ended and will then be deleted. 
Only members of the research team will have access to the data 
files. 
Statistical Methods 
Quantitative data will be analyzed descriptively. Measures of 
mean and variance, including confidence intervals and standard 
deviations, and number and percent for categorical variables, 
will be used to describe the full range of data at baseline and 
postprogram. An intention-to-treat analysis will be incorporated, 
where missing data will be rectified using the last observation 
carried forward [42]. Between-group inferential comparisons 
will not be performed as the study was not designed to be 
powered for this analysis, in concordance with the CONSORT 
(Consolidated Standards of Reporting Trials) extension for pilot 
and feasibility trials [43]. All analyses will be performed using 
IBM SPSS Statistics 26. 
Monitoring 
Data Monitoring 
In this small feasibility trial, it was not deemed necessary to 
employ an independent data monitoring committee. However, 
participant data was screened at T0, T1, and T2 by the research 
team to check for indications of suicidal thoughts on the PHQ-9 
questionnaire. 
Harms 
Participants who indicate they are feeling suicidal at any point 
during the study on the PHQ-9 measure will be provided with 
the contact details of local mental health agencies and 
Samaritans, and will be encouraged to visit their general 
practitioner. We will also contact the MCS administrator. At 
postprogram, all participants’ data will be analyzed to examine 
if any people have reached a probable clinical level of 
depression or anxiety where they previously were not at this 
level. This will be recorded and listed as possible adverse effects 
of the intervention. These participants will be contacted and 
encouraged to visit their general practitioner and will be 
signposted to further sources of support as listed above. 
Auditing 
Auditing of trial conduct will not be necessary. The Hope 
Programme has been developed and tested in various studies, 
so the current feasibility trial will focus on recruitment and 
randomization procedures. 
Ethics and Dissemination 
Research Ethics Approval 
This study was reviewed and approved by the Coventry 
University Ethics Committee (P106024). 
Protocol Amendments 
Any amendments to the protocol will be submitted to the 
Coventry University Ethics Committee for review, and any 






Informed consent will be taken online via Qualtrics. Participants 
will be required to answer “yes” to all consent statements before 
proceeding to the study questionnaires. If participants answer 
“no” to any consent statements, they will be directed to the end 
of the survey and no data will be collected. Consent statements 
for this study are included in Multimedia Appendix 2. 
Confidentiality 
MCS will send names and email addresses of interested 
participants to H4C (with the assent of participants), who will 
email interested participants introductory information and a link 
to the study website (Qualtrics). At the point of consent, 
participants will be assigned a unique identifier (ID) through 
Qualtrics, which will be used to link study data from multiple 
timepoints (T0, T1, T2). Participant data will be identifiable via 
this unique ID for the duration of the study. For the prize draw, 
this unique ID will be linked back to the participant name and 
email address only for email delivery of the prize (£50 Amazon 
voucher). 
Access to Data 
HW, FM, CC, and AT will have access to the final data set. 
Ancillary and Posttrial Care 
There is no postprogram follow-up scheduled after the T1 
questionnaires for IG, and the T2 questionnaires for WLCG. 
However, a participant debrief is provided at the end of the 
study, giving details of where participants can find additional 
support if they feel they need it. 
Dissemination Policy 
The results of the feasibility RCT will be submitted for 
publication via the open access route in a relevant journal (eg, 
Journal of Medical Internet Research), and a lay summary of 
the findings will be presented in a blog on the H4C website for 
participants to access. A link to this blog will be emailed to all 
participants by H4C. 
Results 
Recruitment into this feasibility RCT began in April 2020, with 
all participants completing informed consent and baseline 
questionnaires before being randomized. Data collection from 




This feasibility trial is designed to provide evidence about 
whether it is possible to conduct a definitive trial of a digital 
self-management program for people with cancer. Digital health 
care has become more important than ever in the wake of 
COVID-19, and provision of an acceptable and effective digital 
self-management program for people with cancer is both timely 
and necessary [2,19,20]. 
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Strengths and Limitations 
Digital delivery of the Hope Programme has rapidly become 
essential in light of the COVID-19 pandemic, and the resulting 
social distancing measures required for those who are clinically 
vulnerable or required to quarantine. Owing to recent research 
revealing the number of people with cancer who have 
experienced declining mental health and increasing fear during 
the pandemic [3], the Hope Programme is well placed to deliver 
timely and much-needed support for people with cancer, 
particularly while treatments and contact with health care teams 
are reduced [2]. 
It is noteworthy that there is not always a linear relationship 
between time spent in a digital intervention, the number of 
sessions completed, and participant outcomes [44]. For example, 
it is possible that the participants who access only a couple of 
sessions may be “e-attainers” (as described in [45]). These 
participants may achieve what they need from the program, 
such as practicing gratitude, or gaining reassurance that their 
challenges are shared by others [46]. In our comprehensive 
statistical analyses, we plan to use a combination of data from 
our usability measures and the user engagement data extracted 
from the platform to develop a more thorough understanding 
of engagement and attrition, which can then be used to inform 
the content and design of future versions of the Hope 
Programme. 
A challenge for many digital interventions is completion of 
postprogram questionnaires. Achieving an acceptable 
postprogram questionnaire completion rate is a key criterion 
for progression to a definitive trial. In this feasibility trial, we 
have included entry to a prize draw for those that complete the 
postprogram questionnaires. This will enable us to determine 
whether this is sufficient to secure an acceptable postprogram 
completion rate in this population. Exploring the feasibility of 
achieving acceptable completion rates for questionnaires is 
particularly pertinent with a wait-list control group design. There 
is some evidence that wait-list controls for studies of 
psychological interventions may overestimate intervention 
effects relative to other forms of control group [47]. Wait-list 
control participants are hypothesized to delay taking action 
while they are waiting relative to no active treatment control 
participants [48]. Testing the feasibility of this approach will 
enable us to establish whether this is an acceptable trial design 
and an ethical approach to RCTs for people with cancer in these 
unprecedented times. 
Conflicts of Interest 
GM is the CEO of Hope For The Community (H4C) CIC, and AT is a non-executive director of Hope For The Community (H4C) 
CIC. The other authors declare no conflicts of interest. 
Multimedia Appendix 1 
Hope Programme development and content. 
[DOCX File , 24 KB-Multimedia Appendix 1] 
Multimedia Appendix 2 
Informed consent materials. 
[DOCX File , 27 KB-Multimedia Appendix 2] 
References 
1. Nekhlyudov L, Duijts S, Hudson SV, Jones JM, Keogh J, Love B, et al. Addressing the needs of cancer survivors during 
the COVID-19 pandemic. J Cancer Surviv 2020 Oct;14(5):601-606 [FREE Full text] [doi: 10.1007/s11764-020-00884-w] 
[Medline: 32335850] 
2. Burki TK. Cancer care in the time of COVID-19. Lancet Oncol 2020 May;21(5):628 [FREE Full text] [doi: 
10.1016/S1470-2045(20)30201-1] [Medline: 32213339] 
3. Macmillan Cancer Support. Lost in Lockdown. URL: https://medium.com/macmillan-press-releases-and-statements/ 
lost-in-lockdown-5cefcbb8d76b [accessed 2020-08-20] 
4. Armes J, Crowe M, Colbourne L, Morgan H, Murrells T, Oakley C, et al. Patients' supportive care needs beyond the end 
of cancer treatment: a prospective, longitudinal survey. J Clin Oncol 2009 Dec 20;27(36):6172-6179. [doi: 
10.1200/JCO.2009.22.5151] [Medline: 19884548] 
5. Foster C, Fenlon D. Recovery and self-management support following primary cancer treatment. Br J Cancer 2011 Nov 
08;105 Suppl 1:S21-S28 [FREE Full text] [doi: 10.1038/bjc.2011.419] [Medline: 22048029] 
6. Elliott J, Fallows A, Staetsky L, Smith PWF, Foster CL, Maher EJ, et al. The health and well-being of cancer survivors in 
the UK: findings from a population-based survey. Br J Cancer 2011 Nov 08;105 Suppl 1:S11-S20 [FREE Full text] [doi: 
10.1038/bjc.2011.418] [Medline: 22048028] 
7. Fabi A, Bhargava R, Fatigoni S, Guglielmo M, Horneber M, Roila F, ESMO Guidelines Committee. Electronic address: 
clinicalguidelines@esmo.org. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment. Ann 
Oncol 2020 Mar 12. [doi: 10.1016/j.annonc.2020.02.016] [Medline: 32173483] 
8. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. 
Oncologist 2007;12 Suppl 1:4-10 [FREE Full text] [doi: 10.1634/theoncologist.12-S1-4] [Medline: 17573451] 
https://www.researchprotocols.org/2020/12/e24264 JMIR Res Protoc 2020 | vol. 9 | iss. 12 | e24264 | p. 8 





JMIR RESEARCH PROTOCOLS Wright et al 
9. Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, et al. Fear of cancer recurrence in adult cancer 
survivors: a systematic review of quantitative studies. J Cancer Surviv 2013 Sep;7(3):300-322. [doi: 
10.1007/s11764-013-0272-z] [Medline: 23475398] 
10. Simard S, Savard J, Ivers H. Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. J Cancer Surviv 
2010 Dec;4(4):361-371. [doi: 10.1007/s11764-010-0136-8] [Medline: 20617394] 
11. Koch L, Bertram H, Eberle A, Holleczek B, Schmid-Höpfner S, Waldmann A, et al. Fear of recurrence in long-term breast 
cancer survivors-still an issue. Results on prevalence, determinants, and the association with quality of life and depression 
from the cancer survivorship--a multi-regional population-based study. Psychooncology 2014 May;23(5):547-554. [doi: 
10.1002/pon.3452] [Medline: 24293081] 
12. Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors--a 
systematic review of quantitative studies. Psychooncology 2013 Jan;22(1):1-11. [doi: 10.1002/pon.3022] [Medline: 
22232030] 
13. Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared 
with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol 2013 Jul;14(8):721-732. [doi: 
10.1016/S1470-2045(13)70244-4] [Medline: 23759376] 
14. Inhestern L, Beierlein V, Bultmann JC, Möller B, Romer G, Koch U, et al. Anxiety and depression in working-age cancer 
survivors: a register-based study. BMC Cancer 2017 May 19;17(1):347 [FREE Full text] [doi: 10.1186/s12885-017-3347-9] 
[Medline: 28526007] 
15. Niedzwiedz CL, Knifton L, Robb KA, Katikireddi SV, Smith DJ. Depression and anxiety among people living with and 
beyond cancer: a growing clinical and research priority. BMC Cancer 2019 Oct 11;19(1):943 [FREE Full text] [doi: 
10.1186/s12885-019-6181-4] [Medline: 31604468] 
16. NHS England. The NHS long term plan. URL: https://www.longtermplan.nhs.uk/ [accessed 2020-08-20] 
17. Schellekens MPJ, Wolvers MDJ, Schroevers MJ, Bootsma TI, Cramer AOJ, van der Lee ML. Exploring the 
interconnectedness of fatigue, depression, anxiety and potential risk and protective factors in cancer patients: a network 
approach. J Behav Med 2020 Aug;43(4):553-563 [FREE Full text] [doi: 10.1007/s10865-019-00084-7] [Medline: 31435892] 
18. Brown SL, Fisher PL, Hope-Stone L, Hussain RN, Heimann H, Damato B, et al. Predictors of long-term anxiety and 
depression in uveal melanoma survivors: A cross-lagged five-year analysis. Psychooncology 2020 Aug 10. [doi: 
10.1002/pon.5514] [Medline: 32779313] 
19. Salako O, Okunade K, Allsop M, Habeebu M, Toye M, Oluyede G, et al. Upheaval in cancer care during the COVID-19 
outbreak. Ecancermedicalscience 2020;14:ed97 [FREE Full text] [doi: 10.3332/ecancer.2020.ed97] [Medline: 32269597] 
20. Lonergan PE, Washington Iii SL, Branagan L, Gleason N, Pruthi RS, Carroll PR, et al. Rapid Utilization of Telehealth in 
a Comprehensive Cancer Center as a Response to COVID-19: Cross-Sectional Analysis. J Med Internet Res 2020 Jul 
06;22(7):e19322 [FREE Full text] [doi: 10.2196/19322] [Medline: 32568721] 
21. Wang Y, Lin Y, Chen J, Wang C, Hu R, Wu Y. Effects of Internet-based psycho-educational interventions on mental health 
and quality of life among cancer patients: a systematic review and meta-analysis. Support Care Cancer 2020 
Jun;28(6):2541-2552. [doi: 10.1007/s00520-020-05383-3] [Medline: 32179998] 
22. Morrow-Howell N, Galucia N, Swinford E. Recovering from the COVID-19 Pandemic: A Focus on Older Adults. J Aging 
Soc Policy 2020;32(4-5):526-535. [doi: 10.1080/08959420.2020.1759758] [Medline: 32336225] 
23. Public Health England. Shielding advice. URL: https://tinyurl.com/s5pc7wh [accessed 2020-08-20] 
24. Macmillan Cancer Support. Coronavirus (COVID-19) Guidance for People with Cancer. URL: https://www.macmillan.org.uk/ 
coronavirus/cancer-and-coronavirus [accessed 2020-08-20] 
25. Turner A. A Positive Psychological Group Self-Management Support Programme for Cancer Survivors. 2012 Presented 
at: British Psychosocial Oncology Society Conference; January 19-20, 2012; Leeds, UK. 
26. Turner A, Batehup L, Surendranath S. Hope is key to recovery. Nurs Stand 2011;25(18):20-21. [doi: 10.7748/ns.25.18.20.s26] 
[Medline: 21309317] 
27. Seligman M. Learned Optimism: How to Change Your Mind and Your Life. New York, NY, USA: Pocket Books; 2006. 
28. Seligman M. Authentic Happiness: Using the New Positive Psychology to Realize Your Potential for Lasting Fulfillment. 
New York, NY, USA: Free Press; 2002. 
29. Linley P, Joseph S. Positive psychology in practice. New York, NY, USA: John Wiley & Sons; 2004. 
30. Tugade MM, Fredrickson BL, Barrett LF. Psychological resilience and positive emotional granularity: examining the 
benefits of positive emotions on coping and health. J Pers 2004 Dec;72(6):1161-1190 [FREE Full text] [doi: 
10.1111/j.1467-6494.2004.00294.x] [Medline: 15509280] 
31. Martin F, Wright H, Moody L, Whiteman B, McGillion M, Clyne W, et al. Help to Overcome Problems Effectively for 
Cancer Survivors: Development and Evaluation of a Digital Self-Management Program. J Med Internet Res 2020 May 
19;22(5):e17824 [FREE Full text] [doi: 10.2196/17824] [Medline: 32209529] 
32. Chan A, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-JerićK, et al. SPIRIT 2013 statement: defining standard 
protocol items for clinical trials. Ann Intern Med 2013 Feb 05;158(3):200-207 [FREE Full text] [doi: 
10.7326/0003-4819-158-3-201302050-00583] [Medline: 23295957] 
33. Hope for the Community (H4C) Community Interest Company. URL: https://www.h4c.org.uk [accessed 2020-11-26] 
https://www.researchprotocols.org/2020/12/e24264 JMIR Res Protoc 2020 | vol. 9 | iss. 12 | e24264 | p. 9 
(page number not for citation purposes) 
XSL•FO 
RenderX 
JMIR RESEARCH PROTOCOLS Wright et al 
34. Cohen J. Statistical power analysis for the behavioural sciences. New York, NY, USA: Lawrence Erlbaum Associates; 
1988. 
35. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001 
Sep;16(9):606-613 [FREE Full text] [doi: 10.1046/j.1525-1497.2001.016009606.x] [Medline: 11556941] 
36. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. 
Arch Intern Med 2006 May 22;166(10):1092-1097. [doi: 10.1001/archinte.166.10.1092] [Medline: 16717171] 
37. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-Edinburgh Mental Well-being Scale 
(WEMWBS): development and UK validation. Health Qual Life Outcomes 2007 Nov 27;5:63 [FREE Full text] [doi: 
10.1186/1477-7525-5-63] [Medline: 18042300] 
38. Maheswaran H, Weich S, Powell J, Stewart-Brown S. Evaluating the responsiveness of the Warwick Edinburgh Mental 
Well-Being Scale (WEMWBS): group and individual level analysis. Health Qual Life Outcomes 2012 Dec 27;10:156 
[FREE Full text] [doi: 10.1186/1477-7525-10-156] [Medline: 23270465] 
39. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing 
and measuring activation in patients and consumers. Health Serv Res 2004 Aug;39(4 Pt 1):1005-1026. [doi: 
10.1111/j.1475-6773.2004.00269.x] [Medline: 15230939] 
40. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and 
editorial policy. BMC Med Res Methodol 2010 Jul 16;10:67 [FREE Full text] [doi: 10.1186/1471-2288-10-67] [Medline: 
20637084] 
41. Darlow S, Wen K. Development testing of mobile health interventions for cancer patient self-management: A review. 
Health Informatics J 2016 Sep;22(3):633-650 [FREE Full text] [doi: 10.1177/1460458215577994] [Medline: 25916831] 
42. Dainty AD, Fox M, Lewis N, Hunt M, Holtham E, Timmons S, et al. A mixed methods feasibility study to evaluate the 
use of a low-intensity, nurse-delivered cognitive behavioural therapy for the treatment of irritable bowel syndrome. BMJ 
Open 2014 Jun 17;4(6):e005262-e005262 [FREE Full text] [doi: 10.1136/bmjopen-2014-005262] [Medline: 24939813] 
43. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, PAFS consensus group. CONSORT 2010 
statement: extension to randomised pilot and feasibility trials. BMJ 2016 Oct 24;355:i5239 [FREE Full text] [doi: 
10.1136/bmj.i5239] [Medline: 27777223] 
44. Enrique A, Palacios JE, Ryan H, Richards D. Exploring the Relationship Between Usage and Outcomes of an Internet-Based 
Intervention for Individuals With Depressive Symptoms: Secondary Analysis of Data From a Randomized Controlled Trial. 
J Med Internet Res 2019 Aug 01;21(8):e12775 [FREE Full text] [doi: 10.2196/12775] [Medline: 31373272] 
45. Martinez M. High Attrition Rates in e-Learning: Challenges, Predictors, and Solutions. The E-Learning Guild. 2003. URL: 
https://www.elearningguild.com/pdf/2/071403mgt-l.pdf [accessed 2020-04-27] 
46. Yalom ID, Leszcz M. Theory and Practice of Group Psychotherapy. Fifth Edition. New York, NY, USA: Basic Books; 
2005. 
47. Cunningham JA, Kypri K, McCambridge J. Exploratory randomized controlled trial evaluating the impact of a waiting list 
control design. BMC Med Res Methodol 2013 Dec 06;13:150 [FREE Full text] [doi: 10.1186/1471-2288-13-150] [Medline: 
24314204] 
48. Furukawa TA, Noma H, Caldwell DM, Honyashiki M, Shinohara K, Imai H, et al. Waiting list may be a nocebo condition 
in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand 2014 Sep;130(3):181-192. [doi: 
10.1111/acps.12275] [Medline: 24697518] 
Abbreviations 
CONSORT: Consolidated Standards of Reporting Trials 
GAD-7: Generalized Anxiety Disorder scale 
H4C: Hope for The Community 
MCS: Macmillan Cancer Support 
NHS: National Health Service 
PAM: Patient Activation Measure 
PHQ-9: Patient Health Questionnaire 
PIS: participant information sheet 
SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials 
WEMWBS: Warwick Edinburgh Mental Wellbeing Scale 
https://www.researchprotocols.org/2020/12/e24264 JMIR Res Protoc 2020 | vol. 9 | iss. 12 | e24264 | p. 10 
(page number not for citation purposes) 
XSL•FO 
RenderX 
JMIR RESEARCH PROTOCOLS Wright et al 
Edited by G Eysenbach; submitted 11.09.20; peer-reviewed by C Grimmett, S Ziehfreund ; comments to author 02.10.20; revised 
version received 16.10.20; accepted 20.10.20; published 04.12.20 
Please cite as: 
Wright H, Martin F, Clyne W, Clark CCT, McGillion M, Matouskova G, Turner A 
A Digital Program (Hope) for People Living With Cancer During the COVID-19 Pandemic: Protocol for a Feasibility Randomized 
Controlled Trial 




©Hayley Wright, Faith Martin, Wendy Clyne, Cain C T Clark, Michael McGillion, Gabriela Matouskova, Andrew Turner. 
Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 04.12.2020. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR 
Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on 
http://www.researchprotocols.org, as well as this copyright and license information must be included. 
https://www.researchprotocols.org/2020/12/e24264 JMIR Res Protoc 2020 | vol. 9 | iss. 12 | e24264 | p. 11 
(page number not for citation purposes) 
XSL•FO 
RenderX 
